Science
ctDNA-Based MRD Assessment May Help Identify NSCLC Patients at High Risk of Relapse – IASLC
International Association for the Study of Lung Cancer/LinkedIn

ctDNA-Based MRD Assessment May Help Identify NSCLC Patients at High Risk of Relapse – IASLC

International Association for the Study of Lung Cancer (IASLC) shared on LinkedIn:

“The benefit of durvalumab after CRT varies in unresectable stage III NSCLC, but ctDNA-based MRD assessment may help identify patients at high risk of relapse who could benefit from alternative or intensified treatment strategies.”

Title: ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab

Authors: Henrik Horndalsveen, Vilde Drageset Haakensen, Tesfaye Madebo, Bjørn Henning Grønberg, Tarje Onsøien Halvorsen, Maria Moksnes Bjaanæs, Britina Kjuul Danielsen, Mari Børve, Solveig Kokkvoll, Tonje Sofie Dalen Boda, Åsa Kristina Öjlert, Åslaug Helland

Read the Article

IASLC

You can also read:

Neo-CheckRay: iSBRT and Durvalumab in High-Risk ER+/HER2− Breast Cancer

ctDNA-Based MRD Assessment May Help Identify NSCLC Patients at High Risk of Relapse - IASLC

Åsa Kristina Öjlert Åslaug Helland Bjørn Henning Grønberg Britina Kjuul Danielsen cancer Durvalumab Henrik Horndalsveen IASLC International Association for the Study of Lung Cancer Lung cancer Mari Børve Maria Moksnes Bjaanæs NSCLC OncoDaily Oncology Solveig Kokkvoll Tarje Onsøien Halvorsen Tesfaye Madebo Tonje Sofie Dalen Boda Vilde Drageset Haakensen